Study On Credit Model Innovation Of Commercial Banks To Biomedical Enterprises

Biomedical industry is an important consumer goods industry that relates to living standards.It is influenced by factors such as medicine consumption rigidity,stable progress of new medical reform,release of the new edition essential drug list,and policy support for health service industry.It has great growth potential in the future,and is in a period of rapid development.However,compared to the developed countries,biomedical industry of our country is still in the starting stage of development,and enterprises in the industry are generally faced with capital “bottleneck”.Long period of R&D and clinical trials is an object characteristic in the operation of these enterprises,due to which they are usually faced with the plague of financing difficulty.Limited by common problems such as the low level of R&D,the weak ability to open up markets,and the small scale of capital,these enterprises have weak ability in internal financing,are impeded in debt financing,have an unsound capital market,and have inadequate government subsidy.In reality,biomedical enterprises still rely mainly on bank in financing.Biomedical enterprises are good credit resource for commercial banks.However,limited by the risk prevention mechanism of banks,biomedical enterprises are hard to make breakthrough in financing model,and are limited by credit capital and deadline.In fact,current traditional financing model of commercial banks is mainly asset mortgage and warrandice.But most medical enterprises are majorly light-asset and cannot match the model.The problems in traditional financing model make the enterprises inefficient in financing and limit their economic growth.By doing literature study,bank peer research,enterprise park field survey,and case analysis,we collect materials and perform research.Based on analysis of the development of biomedical enterprise and industry,and the policy and state of commercial bank credit,we focus on problems in the process of commercial banks issuing credits to biomedical enterprises.We discuss about how to innovate and improve commercial bank credit model;and conclude that we should formulate diversified credit models for enterprises in different development stages,including intellectual property pledge,stock-plus-debt combination of investment and financing,standardized products based on Internet data,etc.Finally,we propose experience and insight which are helpful for commercial banks to cooperate more deeply with biomedical enterprises,to catch new interest growth point in credit market,to reach a real win-win terrain for bank and enterprise,to help turning R&D into productive force for biomedical enterprises,and to benefit the society.